These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 31034184)

  • 1. Liraglutide in Children and Adolescents with Type 2 Diabetes.
    Tamborlane WV; Barrientos-Pérez M; Fainberg U; Frimer-Larsen H; Hafez M; Hale PM; Jalaludin MY; Kovarenko M; Libman I; Lynch JL; Rao P; Shehadeh N; Turan S; Weghuber D; Barrett T;
    N Engl J Med; 2019 Aug; 381(7):637-646. PubMed ID: 31034184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.
    Arslanian SA; Hannon T; Zeitler P; Chao LC; Boucher-Berry C; Barrientos-Pérez M; Bismuth E; Dib S; Cho JI; Cox D;
    N Engl J Med; 2022 Aug; 387(5):433-443. PubMed ID: 35658022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
    ; Nathan DM; Lachin JM; Balasubramanyam A; Burch HB; Buse JB; Butera NM; Cohen RM; Crandall JP; Kahn SE; Krause-Steinrauf H; Larkin ME; Rasouli N; Tiktin M; Wexler DJ; Younes N
    N Engl J Med; 2022 Sep; 387(12):1063-1074. PubMed ID: 36129996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
    Libman IM; Miller KM; DiMeglio LA; Bethin KE; Katz ML; Shah A; Simmons JH; Haller MJ; Raman S; Tamborlane WV; Coffey JK; Saenz AM; Beck RW; Nadeau KJ;
    JAMA; 2015 Dec; 314(21):2241-50. PubMed ID: 26624824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.
    Ahmann A; Rodbard HW; Rosenstock J; Lahtela JT; de Loredo L; Tornøe K; Boopalan A; Nauck MA;
    Diabetes Obes Metab; 2015 Nov; 17(11):1056-64. PubMed ID: 26179619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial.
    Seino Y; Kaneko S; Fukuda S; Osonoi T; Shiraiwa T; Nishijima K; Bosch-Traberg H; Kaku K
    J Diabetes Investig; 2016 Jul; 7(4):565-73. PubMed ID: 27182042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).
    Aroda VR; Bailey TS; Cariou B; Kumar S; Leiter LA; Raskin P; Zacho J; Andersen TH; Philis-Tsimikas A
    Diabetes Obes Metab; 2016 Jul; 18(7):663-70. PubMed ID: 26990378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
    Guo W; Tian W; Lin L; Xu X
    Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.
    Seino Y; Yabe D; Sasaki T; Fukatsu A; Imazeki H; Ochiai H; Sakai S
    J Diabetes Investig; 2018 Mar; 9(2):332-340. PubMed ID: 28502112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
    Rosenstock J; Bajaj HS; Janež A; Silver R; Begtrup K; Hansen MV; Jia T; Goldenberg R;
    N Engl J Med; 2020 Nov; 383(22):2107-2116. PubMed ID: 32960514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
    Kelly AS; Auerbach P; Barrientos-Perez M; Gies I; Hale PM; Marcus C; Mastrandrea LD; Prabhu N; Arslanian S;
    N Engl J Med; 2020 May; 382(22):2117-2128. PubMed ID: 32233338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
    D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
    Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.
    Rodbard HW; Bode BW; Harris SB; Rose L; Lehmann L; Jarlov H; Thurman J;
    Diabet Med; 2017 Feb; 34(2):189-196. PubMed ID: 27589252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
    Zinman B; Gerich J; Buse JB; Lewin A; Schwartz S; Raskin P; Hale PM; Zdravkovic M; Blonde L;
    Diabetes Care; 2009 Jul; 32(7):1224-30. PubMed ID: 19289857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.